Personnel Information

写真a

HIRAI Toshinori


Job title

Associate Professor

Field Introduction URL

https://researchmap.jp/t.hirai

To the head of this page.▲

Graduating School 【 display / non-display 】

  • Meiji Pharmaceutical University, Faculty of Pharmaceutical Science, 2009.03, Graduated

To the head of this page.▲

Graduate School 【 display / non-display 】

  • Meiji Pharmaceutical University, Graduate School, Division of Pharmaceutical Sciences, Doctor's Course, 2016.09, Completed

To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2024.04
    -
    2024.09
    Tokyo Medical and Dental University， Tokyo Medical and Dental University， Division of Integrated Facilities， Pharmacy， Associate Professor
  • 2024.10
    -
    Now
    Institute of Science Tokyo， -， Institute of Science Tokyo Hospital， Division of Integrated Facilities， Pharmacy， Associate Professor
To the head of this page.▲

External Career 【 display / non-display 】

  • 2009.04
    -
    2017.05
    , Pharmacist
  • 2017.06
    -
    2018.03
    , Pharmacist
  • 2018.04
    -
    2020.11
    , Senior Staff
  • 2020.04
    -
    Now
    Jikei University, Clinical Pharmacology, Visiting researcher
  • 2020.12
    -
    2024.03
    Mie University Hospital, Department of Pharmacy, Lecturer
To the head of this page.▲

Academic Activity 【 display / non-display 】

  • 2020.07
    -
    2020.11
    Japanese Society of Hospital Pharmacists Evaluation Subcommittee of Prevent and avoid the adverse drug reaction
To the head of this page.▲

Research Areas 【 display / non-display 】

  • Clinical pharmacy

To the head of this page.▲

Qualification Acquired 【 display / non-display 】

  • Pharmacist

  • Medical Technologist

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Population pharmacokinetic analysis of the interaction of digoxin with N-desethylamiodarone in patients with atrial fibrillation and heart failure 2025.04;

  2. Prediction of hyperkalemia occurrence in patients using co-trimoxazole: Clinical adjustment of a Markov model 2025.03; 63 (5): 190-196.

  3. Pharmacokinetic model of drug interaction of tacrolimus with combined administration of CYP3A4 inhibitors voriconazole and clarithromycin after bone marrow transplantation, in press. 2024.10;

  4. Influence of loop diuretics on denosumab-induced hypocalcaemia in osteoporosis: A retrospective observational analysis 2024.10; 27 (10): 1-9.

  5. Hyperkalemic effect of drug–drug interaction between esaxerenone and trimethoprim in patients with hypertension: a pilot study 2024.08; 10 (46): 1-8.

  6. Impact of pharmacist-driven antimicrobial stewardship interventions in a secondary care facility in Japan: A pragmatic quasi-experimental study. 2024.08; ( PubMed, DOI )

  7. The Protective Role of KANK1 in Podocyte Injury 2024.05; 25 (11):

  8. Kinetic-pharmacodynamic model of warfarin for prothrombin time-international normalized ratio in Japanese patients 2024.03; 90 (3): 828-836. ( DOI )

  9. Safety and dose-finding trial of tadalafil administered for fetus in labor: A phase I clinical study. 2024.01; ( PubMed, DOI )

  10. Reduced blood glucose levels by the combination of vadadustat in an elderly patient with chronic kidney disease who was receiving mitiglinide and sitagliptin: a case report 2023.12; 9 (46):

  11. Drug-Drug Interaction Signals between Loop Diuretics and Teicoplanin during Acute Kidney Injury Evaluated using Japanese Spontaneous Adverse Drug Event Reports 2023.09;

  12. Drug interactions of tacrolimus with letermovir and azole antifungals following hematopoietic stem cell transplantation: A retrospective observational analysis 2023.08; 11 (4): ( DOI )

  13. Exploration of the optimal GS-441524 trough concentration for treating COVID-19 2023.08; 62 (2): 106892. ( DOI )

  14. Factors for the development of anemia in patients with newly introduced olaparib: A retrospective case-control study 2023.07; 102 (30): e34123. ( PubMed, DOI )

  15. Safe Co-Administration of Amenamevir with Calcineurin Inhibitors: Case Reports 2023.07; 6 (4): 133-135. ( DOI )

  16. Analysis of Clinical Factors in Olaparib-related Anemia Using Adverse Drug Event Reporting Databases 2023.02; 43 (2): 883-891. ( DOI )

  17. Impact of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation 2023.02; ( DOI )

  18. Comparison of creatinine‐based equations for estimating renal function for digoxin dose adjustment in patients with atrial fibrillation and heart failure 2023.01; 11 (1): ( PubMed, DOI )

  19. Variations in prothrombin time-international normalized ratio caused by drug-drug interaction in patients receiving warfarin: A retrospective observational study 2023.01; ( DOI )

  20. Association between cumulative cisplatin dose and reproductive and sexual functions in patients with malignant ovarian germ cell tumors treated with bleomycin, etoposide, and cisplatin therapy: a case series study 2022.11; 8 (1): ( PubMed, DOI )

  21. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient 2022.10; 60 (10): 439-444. ( DOI )

  22. Evaluation of bleeding and anticoagulation markers by edoxaban and low‐dose cyclosporine: A case series study 2022.10; 43 (5): 192-200. ( DOI )

  23. Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study 2022.09; 40 (6): 1014-1020. ( DOI )

  24. Adverse event profiles of drugs used for treatment of juvenile idiopathic arthritis according to spontaneous reporting system database 2022.09; 60 402-407. ( DOI )

  25. Population kinetic–pharmacodynamic analysis of serum potassium in patients receiving sulfamethoxazole/trimethoprim 2022.09; 131 (5): 380-391. ( PubMed, DOI )

  26. Characteristics of risk factors for acute kidney injury among inpatients administered sulfamethoxazole/trimethoprim: a retrospective observational study 2022.08;

  27. Dual Inhibition of CYP3A4 by Voriconazole and Clarithromycin Influences Tacrolimus Pharmacokinetics: Case Series Study 2022.08; 47 (6): 889-893. ( DOI )

  28. Population Pharmacokinetic Model of Amiodarone and N-Desethylamiodarone Focusing on Glucocorticoid and Inflammation 2022.07; 45 (7): 948-954. ( PubMed, DOI )

  29. Population pharmacokinetic analysis and dosage recommendations for digoxin in Japanese patients with atrial fibrillation and heart failure using real-world data 2022.02; 23 (1): ( DOI )

  30. External Evaluation of a Bayesian Warfarin Dose Optimization Based on a Kinetic-Pharmacodynamic Model 2022.01; 45 (1): 136-142. ( DOI )

  31. Pharmacokinetics of tacrolimus following an overdose in a patient with extreme obesity and genotype CYP3A5*3/*3: a case report 2022; 47 (2): 71-75. ( PubMed, DOI )

  32. Clinical predictors of nephrotoxicity associated with teicoplanin: Meta‐analysis and meta‐regression 2021.11; 130 (1): 110-121. ( PubMed, DOI )

  33. Effect of high-dose sulfamethoxazole/trimethoprim and glucocorticoid use on hyperkalemic event: A retrospective observational study 2021.11; 27 (11): 1607-1613. ( PubMed, DOI )

  34. A meta-analysis of observational studies on anticholinergic burden and fracture risk: evaluation of conventional burden scales 2021.09; 7 (1): ( DOI )

  35. Involvement of the effect of renal hypoperfusion medications on vancomycin trough concentration: A secondary analysis using a retrospective observational data 2021.09; 129 (5): 376-384. ( PubMed, DOI )

  36. Safety profiles of new xanthine oxidase inhibitors: A post-marketing study 2021.05; 59 (05): 372-377. ( PubMed, DOI )

  37. Acute Kidney Injury Impacts on Hypokalemia Associated with Yokukansan Preparation: A Retrospective Observational Study 2021.01; 44 (1): 118-124. ( PubMed, DOI )

  38. Drug-Drug Interaction between Azathioprine and Allopurinol in Patients with Chronic Kidney Disease: A Case Series Study 2021; 4 (5): 170-174. ( DOI )

  39. Geriatric Patients Are at a High Risk of Hypokalemia Associated with Yokukansan Preparation: A Retrospective Cohort Study 2020.11; 43 (11): 1742-1748. ( PubMed, DOI )

  40. Drug-induced thrombotic microangiopathy using the Japanese pharmacovigilance database 2020.10; 58 (10): 543-549. ( PubMed, DOI )

  41. Clinical Predictors of the Hypoglycemic Effect of Sodium–Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study 2020.05; 43 (5): 782-787. ( PubMed, DOI )

  42. Effects of overweight and underweight on the treatment outcomes of rheumatoid arthritis patients treated with biological drugs: A retrospective observational descriptive study 2020.04; 45 (4): 666-673. ( DOI )

  43. Serum Digoxin Concentrations and Outcomes in Patients with Heart Failure and Atrial Fibrillation: A Single-Center Observational Study 2020.03; 51 (2): 57-64. ( DOI )

  44. Relationship between Recurrent Falls and Medication Use during Acute-Care Hospitalization: A Retrospective Descriptive Study 2019.07; 42 (7): 1192-1198. ( DOI )

  45. Renin–angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis 2019.05; 84 (1): 195-202. ( PubMed, DOI )

  46. Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment 2019.02; 75 (6): 859-866. ( PubMed, DOI )

  47. Impact of relative dose intensity on bone marrow suppression induced by S-1: retrospective observational study 2018.12; 4 (1): ( PubMed, DOI )

  48. Evaluation of a pharmacokinetic-pharmacodynamic model for hypouricaemic effects of febuxostat using datasets obtained from real-world patients 2018.07; 84 (10): 2260-2269. ( PubMed, DOI )

  49. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments 2018.06; 43 (6): 829-835. ( DOI )

  50. A retrospective study on the risk factors for bleeding events in warfarin therapy, focusing on renal function 2017.08; 73 (11): 1491-1497. ( PubMed, DOI )

  51. Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid 2016; 39 (6): 1013-1021. ( PubMed, DOI )

▼display all

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. 平井利典. クリアランス理論からどこまで遊離形濃度に迫れるか？. 第41回日本TDM学会・学術大会 2025.07.26

  2. Safety profile of drug-drug interaction between amenamevir with calcineurin inhibitors: case reports. 2023.09.25

  3. Dose optimization of digoxin treatment. 2023.07.24

  4. Clinical risk factors for nephrotoxicity associated with teicoplanin: a meta-analysis. 2021.09.20

  5. Serum digoxin concentration and mortality in patients with heart failure. 2017.09.27

To the head of this page.▲

Others 【 display / non-display 】

  • Clinical technologist，2009.04

  • Pharmacist，2009.04

To the head of this page.▲
 

Campus class subject 【 display / non-display 】

  • Pharmacology，2024 - Now

To the head of this page.▲

External class subject 【 display / non-display 】

  • Tutorial education (Nephrology and Urology)，Mie University

  • Pathophysiology in Nursing Ⅲ (Pharmacology)，Mie University

  • Intensive course for clinical training (Pharmaceutics: drug-drug interaction)，Mie University

To the head of this page.▲